S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Gilead Sciences Announces Third Quarter 2014 Financial Results|
|Gilead Sciences to Present at Two Upcoming Investor Conferences in September|
|Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014|
|Gilead Sciences' stock pulls back from record high close after earnings miss|
|Sovaldi pricing raises debate over drug costs (2014/10/1)|
|Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries|
|Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV|
|European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma|
|Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies|
|Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C|
Click above to view more mutual fund data and stats for gild - Gilead Sciences Inc.